Back to top

Molecular Partners’ Promising Oncology Developments and Strategic Focus Earn Buy Rating

Analyst Charles Zhu of LifeSci Capital maintained a Buy rating on Molecular Partners (MOLN – Research Report), retaining the price target of $12.00...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Molecular Partners AG Sponsored ADR (MOLN)